Interleukin-6: a multifunctional targetable cytokine in human prostate cancer.
about
Beneficial autoimmunity at body surfaces - immune surveillance and rapid type 2 immunity regulate tissue homeostasis and cancerHCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell linesIL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathwayGlucocorticoids and prostate cancer treatment: friend or foe?Prostate cancer and inflammation: the evidence.Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer.The PCa Tumor Microenvironment.Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling.LNCaP prostate cancer cells with autocrine interleukin-6 expression are resistant to IL-6-induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signalingThe role of IL-6 in the radiation response of prostate cancerChronic inflammation and risk of colorectal and other obesity-related cancers: The health, aging and body composition study.SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer.Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment.Immune mediators in the tumor microenvironment of prostate cancer.IL-6/IL-6R as a potential key signaling pathway in prostate cancer development.Disruption of prostate epithelial differentiation pathways and prostate cancer development.The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancerThe role of transcription factors in prostate cancer and potential for future RNA interference therapy.Reversal of Cisplatin resistance by epigallocatechin gallate is mediated by downregulation of axl and tyro 3 expression in human lung cancer cells.Portrait of inflammatory response to ionizing radiation treatment.PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer.Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling.Role of interleukin-6 in cancer progression and therapeutic resistance.Hepcidin regulation in prostate and its disruption in prostate cancer.Changes in periprostatic adipose tissue induced by 5α-reductase inhibitors.Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo.Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals.Plumbagin Inhibits Prostate Carcinogenesis in Intact and Castrated PTEN Knockout Mice via Targeting PKCε, Stat3, and Epithelial-to-Mesenchymal Transition Markers.The common parasite Toxoplasma gondii induces prostatic inflammation and microglandular hyperplasia in a mouse model.Stromal TGF-β signaling induces AR activation in prostate cancer.Interleukin-6 gene -174G>C and -636G>C promoter polymorphisms and prostate cancer risk.Indoleamine-2,3-dioxygenase and Interleukin-6 associated with tumor response to neoadjuvant chemotherapy in breast cancer.Interleukin-6 and Interferon-α Signaling via JAK1-STAT Differentially Regulate Oncolytic versus Cytoprotective Antiviral States.Targeting the IL-6/JAK/STAT3 signalling axis in cancer.The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer.SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma.Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: association with asymptomatic inflammatory prostatitis NIH category IV.Is Eotaxin-1 a serum and urinary biomarker for prostate cancer detection and recurrence?Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/STAT3 and Aurora kinase A pathways in TRAMP mice.
P2860
Q26865509-D18722B3-3935-48D3-B297-BDFF87F946EFQ30278790-AC15B5EF-7BDA-41A6-A566-51871400B877Q33591332-C1CBA5B4-FEBE-44A5-B0C7-FF3A700F584AQ33621387-052B0CDC-AE7A-4732-ABF6-65D9A41B628BQ33642321-E6738CDC-9FE3-4408-8303-22814F5C3D29Q34460302-089880C2-0EC9-4CCC-B932-0DE1D35ACD95Q35603143-717AFE27-5665-458B-987E-22AB706F13D9Q35963362-17E3EA90-EE7B-48F4-B382-B3A6C00E27DFQ36879620-777AE117-FF66-4542-9730-99B2C7581F15Q37028843-2A67797C-D6C5-41EE-82AB-691222A610A5Q37114115-C221E752-DD6B-4C71-8B14-63158A04BEB0Q37533348-0957312A-2517-4022-8644-AB6E2435D393Q37606662-71EAC168-505D-45E0-B35C-75130D857F07Q37701076-201335F6-2BBF-479A-80C7-7E41B5E66020Q37968599-DE87803D-B0FF-44FF-B309-A662F1CC826FQ38160495-6A071AF4-C4F3-44FE-8EEE-C02073B7B1DFQ38176621-4339444A-1775-4ABC-B619-C9DD73D39FADQ38198726-2284AF8E-A4D0-497B-AB5B-C5D8DE4C3B83Q38261470-0183280E-674C-407B-9175-DC10A12069C2Q38364169-A614F67A-AFA7-422F-AE30-CE7762EC3337Q38447860-F3D975AE-B445-4F73-B584-7391880D07BBQ38634034-346AE62B-0A10-4FE8-BBE6-6CCA2626B17EQ38758652-D4EDD944-7A79-4563-AA9F-9CC2186D30F0Q38853625-08E8B144-52C4-4B7D-A558-6665820BCA62Q38889135-62BA933B-7195-4562-8052-A26B92CC0CD4Q38906372-D0688704-FB26-496A-9A45-4D9F0DBF0128Q38911659-47AA9A21-9C11-46B2-B9A8-4FAA044ACCAEQ39174448-6C67A1D3-3225-4F0B-8987-4ACD09613106Q40185493-68B96D43-A8EA-4392-A3BA-0DA477758783Q40215772-485778F5-3D2B-42F4-B88A-2CF3168BFCCFQ43084872-F5E60E1F-0498-4A98-8041-92AA6457DC24Q44788547-6FA60EC7-B6E9-4D87-99AF-BAAF884BE2A8Q47157830-BA24B912-3729-4076-B100-05BB6E054437Q49210539-1520FE6E-78E6-41A0-8BA1-13653DA6E71AQ50191433-5A17B726-CD02-4614-9A38-A72F5E6E06D4Q50431809-7A9B8213-3CDF-463F-B465-3B79A09547EBQ52841133-CACD592A-ACC5-4FEC-A840-AEE24E41FDC2Q53082188-0CBD530E-0261-4131-95C5-0D9B6F5CBA5DQ53372753-EB8588A0-097E-4537-87AC-266096566553Q53784890-EBE84B24-71EF-42A3-8AD7-6A55B17A4F4D
P2860
Interleukin-6: a multifunctional targetable cytokine in human prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Interleukin-6: a multifunctional targetable cytokine in human prostate cancer.
@en
Interleukin-6: a multifunctional targetable cytokine in human prostate cancer.
@nl
type
label
Interleukin-6: a multifunctional targetable cytokine in human prostate cancer.
@en
Interleukin-6: a multifunctional targetable cytokine in human prostate cancer.
@nl
prefLabel
Interleukin-6: a multifunctional targetable cytokine in human prostate cancer.
@en
Interleukin-6: a multifunctional targetable cytokine in human prostate cancer.
@nl
P2860
P921
P1476
Interleukin-6: a multifunctional targetable cytokine in human prostate cancer.
@en
P2093
Martin Puhr
Zoran Culig
P2860
P356
10.1016/J.MCE.2011.05.033
P5008
P577
2011-06-01T00:00:00Z
2012-09-05T00:00:00Z